April 14, 2023 Mary Kay Fenton Re: Retention Agreement Dear Mary Kay:Talaris Therapeutics, Inc. • April 14th, 2023 • Biological products, (no disgnostic substances) • Massachusetts
Talaris Therapeutics, Inc. (the “Company”) greatly appreciates your many contributions especially during these challenging times for the Company. In order to encourage your continued commitment, the Company is offering you the opportunity to receive a retention bonus and change in control benefits as specified below and in the Company’s Amended and Restated Executive Severance and Change in Control Plan (the “CIC Plan”), subject to this “Agreement:”
